Jobs / United States / Pfizer INC
Director/Team Lead, Valuation Center of Excellence (CoE)
Pfizer INC · 🇺🇸 United States - New York - New York City
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 40 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 9 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Pfizer INC paid sponsored hires in similar roles1 certified filing for “Associate Director, Statistics Lead” (Statisticians) in VA: $135k–$135k, median $135k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Pfizer INC
The US Department of Labor certified 40 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 9 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Pfizer INC →
About the role
ROLE SUMMARY The Valuation CoE Team Lead is accountable for the financial valuation of R&D investment decisions and analytical support for business case development. The role ensures that valuations presented to Asset Teams, Category Leadership, and Executive Governance are objective, consistent, and based on common standards, enabling comparable program and portfolio prioritization. This is primarily a Decision Analysis leadership role, supported by strong valuation and modeling expertise. The Team Lead partners with Therapeutic Area-aligned Decision Analysis Directors to define the decision framework, translate development options into aligned scenarios and sensitivities, and provide independent challenge to assumptions from Commercial, Clinical, Regulatory, and Finance. The role owns valuation methodology and financial standards, as well as the development of valuation tools and their integration with forecasting, development cost, PTRS, and portfolio systems. The Team Lead also advances two strategic priorities: building an AI-enabled valuation ecosystem and developing junior Decision Analysis talent. Reports to: Head of PDA Decision Analysis. Direct reports: 3–4 Senior Managers/Managers. Key interfaces: Therapeutic Area Decision Analysis Directors, Enterprise Portfolio Management, Finance, Commercial, Business Development/Corporate Development, and Digital. ROLE RESPONSIBILITIES AI Tooling and Workflow • Set and execute on the roadmap for AI-assisted valuation and decision-support workflows, defining where work should be automated, augmented, or retained as human judgment. • Design reusable prompts, agents, and workflows across approved generative AI platforms to accelerate model development, assumption retrieval, scenario generation, quality checks, and executive deliverables. • Identify and automate recurring analytical tasks; evaluate emerging AI technologies and recommend practical adoption strategies with Digital and business partners. • Establish AI governance, validation, traceability, and human-review controls so all machine-assisted outputs are transparent, reproducible, and fit for governance use. Decision Analysis and Framing • Partner with TA Decision Analysis Directors to frame and pressure-test the business question, decision criteria, options, and key uncertainties before modeling begins. • Apply Decision Quality methods—including decision hierarchies, strategy tables, decision trees, scenario planning, and value of information—to structure complex choices. • Translate development strategies and trade-offs into AI-enabled analytical frameworks, probabilistic analyses, sensitivities, and clear value drivers. • Provide objective challenge to Commercial, Clinical, Regulatory, and Finance assumptions and convert complex findings into concise, actionable recommendations. • Ability to flex and lead decision analysis projects within any therapeutic area if there are potential capacity issues or peak in project volume Valuation Standards and Quality • Together with Head of PDA Decision Analysis and TA Decision Analysis Directors, own valuation metrics used to inform consequential portfolio prioritization and multi-billion dollar investment go/no-go decisions at the Portfolio Management Team (PMT). • Own PDA’s Common Analytical Practices (CAP), including cash flow architecture, risk adjustment, discount rates, eNPV, eIRR, PTRS benchmarks, and standards for approved deviations. • Serve as final quality reviewer for internal pipeline valuations, ensuring consistent assumptions, cross-asset comparability, transparent documentation, and audit-ready outputs before governance review. • Maintain standardized model templates, version control, reusable analytical frameworks, and an AI-enabled knowledge reposito